AIMS: To determine the effects of statins on postprandial lipaemia (PPL) and to study if exercise could enhance statin actions. METHODS:Ten hypercholesteraemic (blood cholesterol 204 ± 36mg dL-1 ; low-density lipoprotein-cholesterol 129 ± 32 36 mg dL-1 ) overweight (body mass index 30 ± 4 kg m-2 ), metabolic syndrome individuals chronically medicated with statins (>6 months) underwent 5-hour PPL tests in 4 occasions in a randomized order: (i) substituting their habitual statin medication by placebo for 96 hours (PLAC trial); (ii) taking their habitual statin medicine (STA trial); (iii) placebo combined with a bout of intense aerobic exercise (EXER+PLAC trial); and (iv) combining exercise and statin medicine (EXER+STA trial). RESULTS: Before the fat meal, statin withdrawal (i.e. PLAC and EXER+PLAC) increased blood triglycerides (TG; 24%), low-density lipoprotein-cholesterol (31%) and total cholesterol (19%; all P < .05) evidencing treatment compliance. After the meal, statin withdrawal increased 5-hour postprandial TG (PPTG) compared to its matched trials (94% higher PLAC vs STA and 45% higher EXER+PLAC vs EXER+STA; P < .05). EXER+PLAC trial did not lower PPTG below PLAC (i.e. incremental AUC of 609 ± 152 vs 826 ± 190 mg dL-1 5 h; P = .09). Adding exercise to statin did not result in larger reductions in PPTG (i.e. EXER+STA vs STA incremental area under the curve of 421 ± 87 vs 421 ± 84 mg dL-1 5 h; P = .99). CONCLUSION: In hypercholesteraemic metabolic syndrome individuals, chronic statin therapy blunts the elevations in TG after a fat meal (i.e. incremental area under the curve of PPTG) reducing the cardiovascular risk associated to their atherogenic dyslipidaemia. However, a single bout of intense aerobic exercise before the high fat meal, does not reduce PPTG but also does not interfere with the effects of statin treatment.
RCT Entities:
AIMS: To determine the effects of statins on postprandial lipaemia (PPL) and to study if exercise could enhance statin actions. METHODS: Ten hypercholesteraemic (blood cholesterol 204 ± 36 mg dL-1 ; low-density lipoprotein-cholesterol 129 ± 32 36 mg dL-1 ) overweight (body mass index 30 ± 4 kg m-2 ), metabolic syndrome individuals chronically medicated with statins (>6 months) underwent 5-hour PPL tests in 4 occasions in a randomized order: (i) substituting their habitual statin medication by placebo for 96 hours (PLAC trial); (ii) taking their habitual statin medicine (STA trial); (iii) placebo combined with a bout of intense aerobic exercise (EXER+PLAC trial); and (iv) combining exercise and statin medicine (EXER+STA trial). RESULTS: Before the fat meal, statin withdrawal (i.e. PLAC and EXER+PLAC) increased blood triglycerides (TG; 24%), low-density lipoprotein-cholesterol (31%) and total cholesterol (19%; all P < .05) evidencing treatment compliance. After the meal, statin withdrawal increased 5-hour postprandial TG (PPTG) compared to its matched trials (94% higher PLAC vs STA and 45% higher EXER+PLAC vs EXER+STA; P < .05). EXER+PLAC trial did not lower PPTG below PLAC (i.e. incremental AUC of 609 ± 152 vs 826 ± 190 mg dL-1 5 h; P = .09). Adding exercise to statin did not result in larger reductions in PPTG (i.e. EXER+STA vs STA incremental area under the curve of 421 ± 87 vs 421 ± 84 mg dL-1 5 h; P = .99). CONCLUSION: In hypercholesteraemic metabolic syndrome individuals, chronic statin therapy blunts the elevations in TG after a fat meal (i.e. incremental area under the curve of PPTG) reducing the cardiovascular risk associated to their atherogenic dyslipidaemia. However, a single bout of intense aerobic exercise before the high fat meal, does not reduce PPTG but also does not interfere with the effects of statin treatment.
Authors: John D Akins; Charles K Crawford; Heath M Burton; Anthony S Wolfe; Emre Vardarli; Edward F Coyle Journal: J Appl Physiol (1985) Date: 2019-02-14
Authors: Steen Larsen; Nis Stride; Martin Hey-Mogensen; Christina N Hansen; Lia E Bang; Henning Bundgaard; Lars B Nielsen; Jørn W Helge; Flemming Dela Journal: J Am Coll Cardiol Date: 2013-01-08 Impact factor: 24.094
Authors: Eric P Plaisance; Michael L Mestek; A Jack Mahurin; J Kyle Taylor; Jose Moncada-Jimenez; Peter W Grandjean Journal: Am J Clin Nutr Date: 2008-07 Impact factor: 7.045
Authors: Paul S Phillips; Richard H Haas; Sergei Bannykh; Stephanie Hathaway; Nancy L Gray; Bruce J Kimura; Georgirene D Vladutiu; John D F England Journal: Ann Intern Med Date: 2002-10-01 Impact factor: 25.391
Authors: Ricardo Mora-Rodriguez; Juan Fernando Ortega; Felix Morales-Palomo; Miguel Ramirez-Jimenez; Alfonso Moreno-Cabañas Journal: Br J Clin Pharmacol Date: 2020-02-18 Impact factor: 4.335
Authors: Laura Alvarez-Jimenez; Felix Morales-Palomo; Alfonso Moreno-Cabañas; Juan Fernando Ortega; Ricardo Mora-Rodriguez Journal: Scand J Med Sci Sports Date: 2022-06-05 Impact factor: 4.645
Authors: Laura Alvarez-Jimenez; Alfonso Moreno-Cabañas; Miguel Ramirez-Jimenez; Felix Morales-Palomo; Juan F Ortega; Ricardo Mora-Rodriguez Journal: J Sport Health Sci Date: 2021-07-21 Impact factor: 13.077